Comparison of Human Hepatoma HepaRG Cells with Human and Rat Hepatocytes in Uptake Transport Assays in Order to Predict a Risk of Drug Induced Hepatotoxicity

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Szabo, Monika ^a   Veres, Zsuzsa ^a   Baranyai, Zsolt ^b   Jakab, Ferenc ^b   Jemnitz, Katalin ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UZSOKI HOSPITAL   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; BROMSULFOPHTHALEIN; CYCLOSPORIN A; ESTRONE SULFATE; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A4; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; ORGANIC ANION TRANSPORTING POLYPEPTIDE 2B1; TAUROCHOLIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL TRANSPORT; CONTROLLED STUDY; DRUG SCREENING; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; LIVER FUNCTION; LIVER TOXICITY; MALE; NONHUMAN; PREDICTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; RISK ASSESSMENT; TOXIC HEPATITIS;

ANIMALS; BIOLOGICAL TRANSPORT; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; CELLS, CULTURED; CHROMANS; CYCLOSPORINE; HEPATOCYTES; HUMANS; RATS; SULFOBROMOPHTHALEIN; SULFONAMIDES; TAUROCHOLIC ACID; THIAZOLIDINEDIONES;

EID: 84875038806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059432     Document Type: Article

References (39)

1. Kaplowitz N, (2001) Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 24: 483-490.
2. McDonald J, Robertson R, (2009) Toxicity testing in the 21st century: a view from the pharmaceutical industry. Toxicol Sci 110: 40-46.
3. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, et al. (2007) The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 168: 66-73.
4. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39(1): 159-234.
5. Madan A, Graham R, Carroll K, Mudra D, Burton A, et al. (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31: 421-431.
6. Hariparsad N, Carr BA, Evers R, Chu X, (2008) Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 36(6): 1046-1055.
7. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, et al. (2006) Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28(1-2): 109-117.
8. Sassa S, Sugita O, Galbraith RA, Kappas A, (1987) Drug metabolism by the human hepatoma cell, HepG2. Biochem Biophys Res Commun 143(1): 52-57.
9. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, et al. (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34(1): 75-83.
10. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, et al. (2007) Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45(4): 957-967.
11. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, et al. (2002) Infection of a human hepatoma cell line by hepatitis B virus. PNAS 99: 15655-15660.
12. Marion MJ, Hantz O, Durantel D, (2010) The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol Biol 640: 261-272.
13. Parent R, Marion MJ, Furio L, Trépo C, Petit MA, (2004) Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology 126: 1147-1156.
14. Anthérieu S, Chesné C, Li R, Camus S, Lahoz A, et al. (2010) Stable expression, activity and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Met Disp 38: 516-525.
15. Jemnitz K, Veres Z, Szabo M, Baranyai Z, Jakab F, et al. (2012) Differential inhibitory effect of cyclosporin A and bosentan on taurocholate uptake in human and rat hepatocytes as a function of culturing time. Toxicol In Vitro 26(1): 174-181.
16. Kemp DC, Zamek-Gliszczynski MJ, Brouwer KLR, (2005) Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol Sci 83: 207-214.
17. Kusuhara H, Sugiyama Y, (2009) In vitro-in vivo extrapolation of transportermediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24: 37-52.
18. Treiber A, Schneiter R, Hausler S, Stieger B, (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35: 1400-1407.
19. Arias IM, (1993) Cyclosporin, the biology of the bile canaliculus, and cholestasis. Gastroenterology 104(5): 1558-1560.
20. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, et al. (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223-231.
21. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, et al. (2001) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167(1): 83-98.
22. Hagenbuch B, Meier PJ, (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflügers Arch Eur J Physiol 447: 653-665.
23. Lengyel G, Veres Z, Szabo P, Vereczkey L, Jemnitz K, (2005) Canalicular and sinusoidal disposition of bilirubin mono- and diglucuronides in sandwich-cultured human and rat primary hepatocytes. Drug Metab Disp 33: 1355-1360.
24. Seglen PO, (1976) Preparation of isolated rat liver cells. Meth Cell Biol 13: 29-83.
25. Jemnitz K, Veres Z, Vereczkey L, (2010) Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol Sc 115: 80-88.
26. Lowry H, Rosebrough NJ, Farr A, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
27. Rippin SJ, Hagenbuch B, Meier PJ, Stieger B, (2001) Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. Hepatology 33: 776-782.
28. Jigorel E, Le Vee M, Boursier-Neyret C, Bertrand M, Fardel O, (2005) Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes. Drug Metab Dispos 33(10): 1418-1422.
29. Stieger B, (2011) Drug transporters: The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 201: 205-259.
30. Kostrubsky VE, Strom SC, Hanson J, Urda E, Rose K, et al. (2003) Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 76: 220-228.
31. Leslie EM, Watkins PB, Kim R, Brouwer KLR, (2007) Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Toxicol 32: 11170-11178.
32. Kouzuki H, Suzuki H, Stieger B, Meier PJ, Sugiyama Y, (2000) Characterization of the transport properties of organic anion transporting polypeptide 1 (Oatp1) and Na(+)/taurocholate cotransporting polypeptide (Ntcp): Comparative studies on the inhibitory effect of their possible substrates in hepatocytes and cDNA-transfected COS-7 cells. J Pharmacol Exp Ther 292: 505-511.
33. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B, (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26: 1667-1677.
34. Alpini G, Glaser S, Phinizy JL, Kanno N, Francis H, et al. (2001) Regulation of cholangiocyte apical bile acid transporter (ABAT) activity by biliary bileacids: different potential compensatory changes for intrahepatic and extrahepatic cholestasis. Gastroenterology 120: A6.
35. Azer SA, Stacey NH, (1993) Cyclosporine-induced interference with uptake of bile acids by human hepatocytes. Transplant Proc 25: 2892-2893.
36. Stacey NH, Kotecka B, (1988) Inhibition of taurocholate and ouabain transport in isolated rat hepatocytes by cyclosporin A. Gastroenterology. 95: 780-786.
37. Treiber A, Schneiter R, Delahaye S, Clozel M, (2004) Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther 308: 1121-1129.
38. Smith MT, (2003) Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 16(6): 679-687.
39. Kotani N, Maeda K, Debori Y, Camus S, Li R, et al. (2012) Expression and transport function of drug uptake transporters in differentiated HepaRG cells. Mol Pharmaceutics 9 (12): 3434-3441.